Cholesterol Test Market Size, Share & Trends Analysis Report By Product Type (Test Kits, Test Strips, Others), By Test Type (Total Cholesterol Test, HDL Test, LDL Test, Triglycerides Test), By End-User (Hospitals, Diagnostic Centers, Home Care Settings, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Cholesterol Test Market Size

The global cholesterol test market size was valued at USD 8.24 billion in 2024 and is projected to grow from USD 9.12 billion in 2025 to USD 16.10 billion by 2033, exhibiting a CAGR of 7.4% during the forecast period (2025-2033).

A cholesterol test, also known as a lipid panel or lipid profile, is a blood test used to measure cholesterol levels and other fats in the bloodstream. It evaluates total cholesterol, low-density lipoprotein (LDL or "bad" cholesterol), high-density lipoprotein (HDL or "good" cholesterol), and triglycerides. This test is crucial for assessing the risk of cardiovascular diseases such as heart attacks and strokes. Regular monitoring of cholesterol levels helps in early detection and management of hyperlipidemia, guiding lifestyle changes or medical interventions to maintain heart health.

The global cholesterol test market is driven by rising awareness of the importance of cardiovascular health affected by high cholesterol levels, the growing prevalence of lifestyle-related diseases, and advances in testing technology. The market is growing as rising obesity rates drive health concerns globally, leading to increased demand for early diagnosis.

The below graph shows the prevalence of obesity in adults,2021-2023, U.S.

Source: Straits Research, National Center for Health Statistics

The above bar graph indicates that obesity rates are highest among individuals aged 40-59, emphasizing the importance of regular cholesterol monitoring in this age group, thereby requiring advanced and efficient cholesterol testing methods driving the market growth.

Cholesterol Test Market Trends

Rising demand for cholesterol testing

The study of lipid profiles in biological systems (lipidomics) is emerging as a significant area in diagnosis. This developing field of science allows for a more thorough examination of lipids, aiding in the early diagnosis and treatment of cardiovascular diseases.

• For instance, in March 2022, Thermo Fisher Scientific launched a highly advanced lipidomics platform to test cholesterol comprehensively, thus helping researchers explore more detailed lipid profiles and better understand cardiovascular health compared to conventional cholesterol testing methods.

This increasing demand in lipidomics is set to improve significantly demand for cholesterol testing, providing more accurate results in early diagnosis.

Shift towards integration of AI in cholesterol testing

The integration of artificial intelligence into cholesterol testing revolutionizes the cardiovascular health assessment procedure. AI refines the old cholesterol testing technique by providing highly accurate, prompt, and personalized results.

• For instance, in August 2023, a study released in ScienceDirect investigated the application of AI-driven models to improve cholesterol testing and profiling to yield more precise evaluations of cardiovascular disease risk.

Such research study illustrates that integrating AI into cholesterol testing enhances diagnostic precision, thus leading to efficient and personalized cardiovascular care.

Cholesterol Test Market Growth Factors

Increasing prevalence of cardiovascular diseases

The increasing prevalence of cardiovascular disease has boosted the demand for cholesterol testing, as these tests are crucial in diagnosing cardiovascular conditions and analyzing lipid profiles. The abnormal cholesterol level can lead to a serious outcome, such as heart attack and stroke.

• For instance, in December 2022, the World Health Organization (WHO) identified cardiovascular diseases as the primary cause of death globally, stressing the significance of routine cholesterol screenings to help lower the risk of heart disease.

Thus, the growing prevalence of cardiovascular diseases and the global demand for improved cholesterol testing are driving the market.

Government initiatives for cholesterol testing

Many countries have launched public awareness campaigns and established guidelines for conducting regular cholesterol tests. This strategy aims to increase accessibility to cholesterol testing, educate the public about monitoring lipid levels, and integrate cholesterol testing into national health agendas.

• For instance, in April 2024, a study was reported by the National Heart, Lung and Blood Institute, highlighting the importance of cholesterol testing, recommending it for individuals under 19 years old, thereby promoting awareness of cholesterol monitoring among the younger generation.

Such government initiatives are crucial for improving countries’ health infrastructure and overall patient outcomes.

Market Restraining Factors

Expensive procedures for cholesterol testing

The high cost of cholesterol testing is a significant challenge for the global cholesterol test market. Advanced diagnostic platforms like lipidomic profiling and AI-driven cholesterol assessments require sophisticated equipment and highly trained personnel, driving up the cost of testing. This financial barrier limits access to regular cholesterol screenings, especially in low-resource settings, reducing early detection and prevention of cardiovascular diseases.

• For example, Comprehensive lipid testing using advanced platforms can cost up to USD 150 per test, making it unaffordable for many patients without adequate health insurance coverage. This hinders widespread adoption in low-income regions.

Market Opportunities

Technological advancements in cholesterol testing devices

New technologies that improve test device testing accuracy, speed, and ease open opportunities in the global cholesterol test industry. The portable, handheld cholesterol test tools facilitate easier access for healthcare providers and end-users to provide quick results in multiple settings from the hospital to use at home. Innovations in cholesterol testing devices are creating significant market opportunities. Portable and handheld cholesterol test kits provide fast, reliable results, enabling point-of-care testing in clinics, pharmacies, and at home. These advancements improve patient compliance and promote proactive health monitoring, particularly for individuals at risk of cardiovascular diseases.

• For instance, in January 2022, a study published in the National Library of Medicine examined the influence of advanced cholesterol testing technologies. It underlined the necessity of including high-resolution analytical tools for precise cholesterol profiling that would provide more personalized cardiovascular care.

This growing demand for advanced technologies presents a lucrative market opportunity for cholesterol testing.

Regional Analysis

North America: dominant region with 39.8% market share

North America holds a dominant global market share, accounting for 39.8% of global revenue. This is primarily due to the region's advanced healthcare infrastructure, high public awareness of cardiovascular health, and widespread adoption of preventive healthcare measures. North American consumers are increasingly focused on early diagnosis and proactive management of their health, particularly regarding cholesterol and heart disease.

Furthermore, government initiatives that improve public health, such as the Centers for Disease Control and Prevention’s (CDC) campaigns on heart disease prevention, further contribute to the demand for cholesterol testing services. Moreover, substantial healthcare investments from both the public and private sectors help sustain the growth of testing services, making North America the leading market globally.

Asia Pacific: fastest growing region with the highest market CAGR

The Asia-Pacific region is forecasted to experience the fastest CAGR during the forecast period, driven by a combination of factors, including increased health awareness, rising rates of cardiovascular diseases, and expanding access to healthcare services. As Asia's middle class grows and urbanized, a shift toward preventive healthcare leads to higher demand for cholesterol testing.

Furthermore, government initiatives to tackle the rising burden of lifestyle diseases, such as obesity and diabetes, are accelerating the adoption of regular health screenings. The rising prevalence of cardiovascular diseases in countries like China and India, compounded by risk factors like poor diet and sedentary lifestyles, is significantly contributing to this growth. For example, the Indian government’s National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS) has promoted awareness and facilitated screenings for heart disease, including cholesterol tests, especially in rural and underserved areas.

Country Insights

The market is experiencing dynamic growth and diversification across the globe, with each country contributing uniquely to advancing this transformative field.

• U.S.- The U.S. dominates the market due to its sophisticated healthcare infrastructure, high prevalence of diseases associated with cardiovascular conditions, and comprehensive government initiatives toward preventive care. Moreover, advanced R&D and AI-driven diagnostics enhance accessibility and accuracy. For instance, researchers assessed trends in cholesterol screening, lipid levels, and the use of lipid-lowering medications among U.S. adults. These findings revealed significant changes over the two-decade period, providing insights into public health interventions and the evolving landscape of cardiovascular risk management.
• Germany– Germany is one of the leading countries in the market due to strong government initiatives for preventive healthcare, advanced infrastructure, and adoption of advanced diagnostic technologies; the country emphasizes early detection and management of cardiovascular diseases while creating awareness about cholesterol-related health risks. For instance, in June 2023, research published in Atherosclerosis Plus focused on sex-specific differences in the management of familial hypercholesterolemia (FH) in Germany, where the estimated prevalence of FH is 1 in 300 in the population, thus driving the market for cholesterol test in the country.
• France- France is one of the leading countries in the market due to advanced health infrastructure and public awareness regarding heart health, followed by a more proactive approach toward preventive healthcare. The several initiatives of the French government have encouraged the country to ensure cholesterol testing to minimize the burden of cardiovascular disease. In addition, research in medicine conducted in France and the incorporation of modern diagnostic technologies support the development of the market.
• China- The China market for cholesterol tests is driven by its large population, increasing consciousness of cardiovascular health, and the rapid development in healthcare infrastructure. The country is experiencing an increasing prevalence of lifestyle-related diseases, such as obesity and diabetes, thereby increasing demand for cholesterol tests. For instance, in August 2023, according to a survey in China, the prevalence of dyslipidemia among adults aged ≥18 years was 35.6%, leading to the increasing trend of cardiovascular diseases and the growing demand for cholesterol testing, thus boosting the market in the region.
• India- India, with its vast population, is experiencing rapid growth in the market due to rising incidence of lifestyle disorders, awareness regarding preventive health, and government initiatives. For instance, in January 2025, the Indian Government, via its Press Information Bureau (PIB), reaffirmed its commitment towards non-communicable devices (NCDs) like cardiovascular diseases.
• Japan – Japan is one of the leading countries in the market due to the high prevalence and prevalence of age-related and lifestyle-related conditions and the higher percentage of cardiac problems. Additionally, public health initiatives and government regular health check-ups contribute to the country’s market growth.
• Brazil – Brazil, due to its massive population, with a growing prevalence of obesity and cardiovascular conditions and increasing awareness of preventive care, is experiencing growth in the cholesterol test industry. The country is also registered to have an expanded health infrastructure and government initiatives in upholding access to diagnostic services, boosting demand for cholesterol testing.

Segmentation Analysis

The global cholesterol test market is segmented based on product, test type, application, and service provider.

By product

The testing kits segment dominates the market due to its comprehensive and ready-to-use set for evaluating all cholesterol levels, such as total cholesterol, LDL, HDL, and triglycerides. These are popular for easy use, accuracy, and prompt results and are commonly available in clinics, hospitals, and homes.

• For instance, in November 2024, UCLPartners announced that a new rapid cholesterol test is being carried out in North East London pharmacies to detect cardiovascular diseases faster and for early management.

By test type

The LDL Cholesterol Tests segment is the largest market share within cholesterol tests, dominating the market. As an important measure of cardiovascular risk, LDL cholesterol is critical in diagnosing and treating conditions, including heart disease and hyperlipidemia. An increase in cardiovascular diseases, awareness about cholesterol management, and innovations in the technologies used for LDL tests have all been factors that have edged this segment to continue leading the market.

By application

Cardiovascular diseases lead the cholesterol test market due to the rising prevalence of heart disorders and demands for early diagnosis. Testing cholesterol levels is necessary for estimating cardiovascular risk, thus increasing the demand for cholesterol testing.

• For instance, in May 2023, the World Health Organization (WHO) stated that cardiovascular diseases are still the leading cause of death globally, accounting for around 17.9 million deaths annually, and high cholesterol is one of the significant risk factors.

By Service Provider

The hospital and clinics dominate the cholesterol test market as they are better equipped, technologically advanced for diagnosis, and have a significant patient population at their access. They offer an integrated lipid profile check-up to allow early diagnosis and treatment of cholesterol-related diseases, mainly cardiovascular diseases. They are preferred options by patients for follow-up and regular check-ups in preventive healthcare practices.

Company Market Share

Key players in the industry are focused on adopting key business strategies, such as strategic collaborations, product approvals, acquisitions, and product launches, to gain a strong foothold in the market.

Verichem Laboratories Inc.: An emerging player in the cholesterol test market

Verichem Laboratories Inc. is one of the leading suppliers of precise reference materials and clinical standards meant to facilitate in vitro diagnostics. The company is notably recognized for its expertise in chemistry-based solutions; it has good lipid testing experience, like cholesterol assays. In turn, Verichem assists laboratories around the globe in remaining in compliance with all regulatory requirements while providing higher levels of diagnostic quality to meet patient care goals better.

Recent developments by Verichem Laboratories Inc.:

• In October 2024, Verichem Laboratories, new reference materials for the calibration and verification testing of cholesterol assays were released to address the booming demand for quality diagnostic equipment, thereby maintaining reliability and accuracy during cholesterol tests.

Recent Developments 

• October 2024- Novartis released a new innovative therapy that could reduce bad cholesterol and help prevent heart attacks. Cholesterol testing and management are now more vital in searching for cardiovascular disease solutions.
• September 2024- Quest Diagnostics finalized its acquisition of some lab assets from Allina Health. The acquisition enhances Quest Diagnostics's ability to cater to a more extensive population by providing comprehensive diagnostic services like cholesterol testing.

Analyst Opinion

As per our analyst, the global market is expected to grow with increasing global cases of cardiovascular diseases, growing preventive healthcare awareness, and advances in diagnostic technologies. The primary driving force for the demand for cholesterol testing is the aging population in developed regions like Japan and the U.S. Also, improving health care infrastructure, government initiatives, and increasing the middle-class population in countries like India and Brazil contribute to market expansion.

Additionally, the advancement of testing methods includes point-of-care testing and home-based kits, which promote access and ease of use; strategic acquisitions by leading manufacturers further contribute to the cholesterol test industry globally.